Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    22825216 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: DCC-2036
2 Active, not recruiting Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia;   Ph+ Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
3 Completed
Has Results
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Bosutinib;   Drug: imatinib

Study has passed its completion date and status has not been verified in more than two years.